$DARE
Dare Bioscience, Inc.

2018 Q1 Form 10-Q Financial Statement

#000156459018013316 Filed on May 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $0.00 $1.192M
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.400M $200.0K
YoY Change 600.0% -93.59%
% of Gross Profit
Research & Development $1.087M $4.651M
YoY Change -76.64% -52.4%
% of Gross Profit
Depreciation & Amortization $0.00 $66.00K
YoY Change -100.0% 8.2%
% of Gross Profit
Operating Expenses $7.677M $6.738M
YoY Change 13.94% -47.72%
Operating Profit -$7.677M
YoY Change
Interest Expense $797.0K
YoY Change 20.21%
% of Operating Profit
Other Income/Expense, Net $11.74K -$793.0K
YoY Change -101.48% 21.25%
Pretax Income -$7.670M -$240.0K
YoY Change 3095.83% -98.23%
Income Tax
% Of Pretax Income
Net Earnings -$7.666M -$6.339M
YoY Change 20.93% -53.19%
Net Earnings / Revenue -531.8%
Basic Earnings Per Share
Diluted Earnings Per Share -$883.6K -$263.7K
COMMON SHARES
Basic Shares Outstanding 8.685M 29.02M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.63M $12.03M
YoY Change 29.93% -80.12%
Cash & Equivalents $15.63M $94.02K
Short-Term Investments
Other Short-Term Assets $290.0K $2.450M
YoY Change -88.16%
Inventory
Prepaid Expenses $290.9K
Receivables $1.139M
Other Receivables $0.00
Total Short-Term Assets $15.94M $15.61M
YoY Change 2.15% -74.86%
LONG-TERM ASSETS
Property, Plant & Equipment $114.0K
YoY Change -83.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $690.0K $230.0K
YoY Change 200.0% 0.0%
Total Long-Term Assets $685.2K $344.0K
YoY Change 99.19% -62.61%
TOTAL ASSETS
Total Short-Term Assets $15.94M $15.61M
Total Long-Term Assets $685.2K $344.0K
Total Assets $16.63M $15.95M
YoY Change 4.24% -74.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $810.0K $644.0K
YoY Change 25.78% -70.59%
Accrued Expenses $3.538M
YoY Change -36.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $807.6K $6.682M
YoY Change -87.91% -57.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $162.0K
YoY Change -100.0% -78.96%
Total Long-Term Liabilities $0.00 $1.530M
YoY Change -100.0% -86.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $807.6K $6.682M
Total Long-Term Liabilities $0.00 $1.530M
Total Liabilities $810.5K $8.212M
YoY Change -90.13% -69.63%
SHAREHOLDERS EQUITY
Retained Earnings -$19.90M -$207.0M
YoY Change -90.39%
Common Stock $35.75M $214.8M
YoY Change -83.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.82M $7.741M
YoY Change
Total Liabilities & Shareholders Equity $16.63M $15.95M
YoY Change 4.25% -74.69%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$7.666M -$6.339M
YoY Change 20.93% -53.19%
Depreciation, Depletion And Amortization $0.00 $66.00K
YoY Change -100.0% 8.2%
Cash From Operating Activities -$2.119M -$50.00K
YoY Change 4137.77% -99.62%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.10M $62.00K
YoY Change 16190.32% 51.22%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $10.20M 100.0K
YoY Change 10097.81% -105.29%
NET CHANGE
Cash From Operating Activities -$2.119M -50.00K
Cash From Investing Activities
Cash From Financing Activities $10.20M 100.0K
Net Change In Cash $8.065M 50.00K
YoY Change 16030.36% -100.32%
FREE CASH FLOW
Cash From Operating Activities -$2.119M -$50.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
284206
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
311571
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
193495
CY2018Q1 us-gaap Assets Current
AssetsCurrent
15944791
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
723191
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
966653
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
392
CY2017Q4 us-gaap Liabilities
Liabilities
967045
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
290877
CY2017Q4 us-gaap Goodwill
Goodwill
5187519
CY2018Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
807607
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
807607
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2888
CY2018Q1 us-gaap Liabilities
Liabilities
810495
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
1142
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
605
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-31826
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35747609
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19896569
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
15820356
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16630851
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11422161
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11422161
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1303189
CY2018Q1 dare License Fee
LicenseFee
100000
CY2018Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5187519
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11744
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15400
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-7665617
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-13746
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7679363
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8684550
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18080
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8065180
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
49405
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44614
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94019
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9124
CY2018Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-255318
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-20694
CY2018Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-193495
CY2017Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2800
CY2018Q1 dare Increase Decrease In Other Assets And Deferred Charges
IncreaseDecreaseInOtherAssetsAndDeferredCharges
-37131
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-159047
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
180660
CY2017Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
15405
CY2018Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
2496
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2118887
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-50595
CY2018Q1 dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
10197813
CY2017Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
100000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10197813
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
100000
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-13746
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.26
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of stock-based compensation, goodwill impairment and purchase accounting. Actual results could differ from those estimates and could materially affect the reported amounts of assets, liabilities and future operating results.</p></div>
CY2018Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-28
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q1 dare Number Of Clinical Stage Assets Assembled As Portfolio
NumberOfClinicalStageAssetsAssembledAsPortfolio
2
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000
CY2018Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
CY2017Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2018Q1 dare Stock Purchase Transaction Completion Date
StockPurchaseTransactionCompletionDate
2017-07-19
CY2018Q1 dare Stock Option Modification Approval Date
StockOptionModificationApprovalDate
2017-03-19
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7500000
CY2017Q3 us-gaap Goodwill
Goodwill
12700000
CY2018Q1 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
40103
CY2018Q1 dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P2Y1M17D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
539896
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3500
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
526338
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.40
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.37
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.21
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0252
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.22
CY2018Q1 dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000
CY2018Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.70
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.00
CY2018Q1 dare Gross Proceeds From Offering Of Common Stock And Warrants
GrossProceedsFromOfferingOfCommonStockAndWarrants
10300000
CY2018Q1 dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
9400000
CY2018Q1 dare Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P5Y
CY2018Q1 dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
0
CY2017Q1 dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
0
CY2018Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3751002
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4294398
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10149

Files In Submission

Name View Source Status
0001564590-18-013316-index-headers.html Edgar Link pending
0001564590-18-013316-index.html Edgar Link pending
0001564590-18-013316.txt Edgar Link pending
0001564590-18-013316-xbrl.zip Edgar Link pending
dare-10q_20180331.htm Edgar Link pending
dare-20180331.xml Edgar Link completed
dare-20180331.xsd Edgar Link pending
dare-20180331_cal.xml Edgar Link unprocessable
dare-20180331_def.xml Edgar Link unprocessable
dare-20180331_lab.xml Edgar Link unprocessable
dare-20180331_pre.xml Edgar Link unprocessable
dare-ex311_11.htm Edgar Link pending
dare-ex312_13.htm Edgar Link pending
dare-ex321_7.htm Edgar Link pending
dare-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201805131632007944732.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending